Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.
Medtech VCs stay active despite tough conditions
Medtech VC investment rebounded significantly to $3.3 billion in Q1 as investors piled into high-quality companies despite historically low deal volume, our Q1 2024 Medtech Report explains.
- The largest deal went to early cancer detection startup Freenome, which raised a $254 million late-stage round led by Roche Venture Fund.
- Public medtech valuations have stabilized, and there are pockets of rising valuations within medical devices, consumer health, and life sciences. But exits remain hard to come by.
- The report dives into two areas of emerging opportunities—whole-body scans and cardiac arrest prevention and treatment—that investors should be watching.
Table of contents
| Vertical update | 3 |
| Q1 2024 timeline | 4 |
| Medtech landscape | 5 |
| Medtech VC and PE ecosystem market map | 6 |
| VC and PE activity | 7 |
| Emerging opportunities | 11 |
| Whole-body scans | 12 |
| Cardiac arrest prevention and treatment | 14 |
| Select company highlights | 16 |
| Healthy.io | 17 |
| Paige AI | 19 |
| Appendix | 21 |